vs
Side-by-side financial comparison of Beam Global (BEEM) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $9.0M, roughly 1.0× Beam Global). STRATA Skin Sciences, Inc. runs the higher net margin — 0.6% vs -25.8%, a 26.4% gap on every dollar of revenue. On growth, Beam Global posted the faster year-over-year revenue change (6.7% vs -3.0%). STRATA Skin Sciences, Inc. produced more free cash flow last quarter ($-551.0K vs $-3.8M). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs -21.2%).
Suntory Global Spirits Inc., formerly known as Beam Suntory, Inc., and before that as Beam, Inc., is an American beverage company that is a subsidiary of Suntory Holdings, a Japanese multinational beverage conglomerate. The company produces alcoholic beverages.
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
BEEM vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.0M | $9.3M |
| Net Profit | $-2.3M | $58.0K |
| Gross Margin | 17.8% | 61.8% |
| Operating Margin | -29.3% | 5.3% |
| Net Margin | -25.8% | 0.6% |
| Revenue YoY | 6.7% | -3.0% |
| Net Profit YoY | 49.6% | 101.3% |
| EPS (diluted) | — | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.0M | $9.3M | ||
| Q3 25 | $5.8M | $6.9M | ||
| Q2 25 | $7.1M | $7.7M | ||
| Q1 25 | $6.3M | $6.8M | ||
| Q4 24 | $8.5M | $9.6M | ||
| Q3 24 | $11.5M | $8.8M | ||
| Q2 24 | $14.8M | $8.4M | ||
| Q1 24 | $14.6M | $6.8M |
| Q4 25 | $-2.3M | $58.0K | ||
| Q3 25 | $-4.9M | $-1.6M | ||
| Q2 25 | $-4.3M | $-2.6M | ||
| Q1 25 | $-15.5M | $-2.1M | ||
| Q4 24 | $-4.6M | $-4.6M | ||
| Q3 24 | $1.3M | $-2.1M | ||
| Q2 24 | $-4.9M | $-91.0K | ||
| Q1 24 | $-3.0M | $-3.4M |
| Q4 25 | 17.8% | 61.8% | ||
| Q3 25 | -0.5% | 60.4% | ||
| Q2 25 | 20.3% | 56.2% | ||
| Q1 25 | 7.9% | 53.5% | ||
| Q4 24 | 26.3% | 61.4% | ||
| Q3 24 | 10.7% | 60.1% | ||
| Q2 24 | 15.9% | 59.0% | ||
| Q1 24 | 10.2% | 45.6% |
| Q4 25 | -29.3% | 5.3% | ||
| Q3 25 | -84.2% | -16.9% | ||
| Q2 25 | -63.1% | -30.1% | ||
| Q1 25 | -245.8% | -25.0% | ||
| Q4 24 | -60.1% | -44.7% | ||
| Q3 24 | 11.2% | -18.2% | ||
| Q2 24 | -32.3% | -5.7% | ||
| Q1 24 | -20.9% | -42.7% |
| Q4 25 | -25.8% | 0.6% | ||
| Q3 25 | -84.1% | -23.4% | ||
| Q2 25 | -60.5% | -33.6% | ||
| Q1 25 | -245.5% | -31.2% | ||
| Q4 24 | -54.5% | -47.6% | ||
| Q3 24 | 11.3% | -23.6% | ||
| Q2 24 | -33.2% | -1.1% | ||
| Q1 24 | -20.9% | -49.8% |
| Q4 25 | — | $0.14 | ||
| Q3 25 | $-0.28 | $-0.36 | ||
| Q2 25 | $-0.28 | $-0.62 | ||
| Q1 25 | $-1.04 | $-0.51 | ||
| Q4 24 | $-0.31 | $-2.01 | ||
| Q3 24 | $0.09 | $-0.51 | ||
| Q2 24 | $-0.34 | $-0.03 | ||
| Q1 24 | $-0.21 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $969.0K | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $24.8M | $2.9M |
| Total Assets | $42.7M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $969.0K | $7.9M | ||
| Q3 25 | $3.3M | $7.1M | ||
| Q2 25 | — | $6.0M | ||
| Q1 25 | — | $6.5M | ||
| Q4 24 | $4.6M | $7.3M | ||
| Q3 24 | — | $7.1M | ||
| Q2 24 | — | $5.5M | ||
| Q1 24 | — | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $24.8M | $2.9M | ||
| Q3 25 | $26.5M | $1.3M | ||
| Q2 25 | $26.9M | $532.0K | ||
| Q1 25 | $26.7M | $3.0M | ||
| Q4 24 | $41.3M | $5.0M | ||
| Q3 24 | $46.4M | $9.4M | ||
| Q2 24 | $43.4M | $9.5M | ||
| Q1 24 | $46.9M | $9.4M |
| Q4 25 | $42.7M | $30.5M | ||
| Q3 25 | $44.6M | $30.7M | ||
| Q2 25 | $46.7M | $29.5M | ||
| Q1 25 | $46.8M | $33.0M | ||
| Q4 24 | $61.5M | $34.9M | ||
| Q3 24 | $67.3M | $39.4M | ||
| Q2 24 | $71.9M | $38.8M | ||
| Q1 24 | $75.7M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.8M | $-239.0K |
| Free Cash FlowOCF − Capex | $-3.8M | $-551.0K |
| FCF MarginFCF / Revenue | -42.3% | -5.9% |
| Capex IntensityCapex / Revenue | 0.6% | 3.4% |
| Cash ConversionOCF / Net Profit | — | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-11.8M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.8M | $-239.0K | ||
| Q3 25 | $-4.6M | $-64.0K | ||
| Q2 25 | $-318.0K | $-1.9M | ||
| Q1 25 | $-1.8M | $-550.0K | ||
| Q4 24 | $859.0K | $703.0K | ||
| Q3 24 | $-3.0M | $-302.0K | ||
| Q2 24 | $2.9M | $591.0K | ||
| Q1 24 | $-3.0M | $-804.0K |
| Q4 25 | $-3.8M | $-551.0K | ||
| Q3 25 | $-5.1M | $-1.1M | ||
| Q2 25 | $-1.1M | $-2.0M | ||
| Q1 25 | $-1.8M | $-749.0K | ||
| Q4 24 | $462.0K | $199.0K | ||
| Q3 24 | $-3.1M | $-364.0K | ||
| Q2 24 | $2.8M | $246.0K | ||
| Q1 24 | $-3.1M | $-1.5M |
| Q4 25 | -42.3% | -5.9% | ||
| Q3 25 | -87.9% | -15.6% | ||
| Q2 25 | -15.2% | -26.1% | ||
| Q1 25 | -28.7% | -11.0% | ||
| Q4 24 | 5.4% | 2.1% | ||
| Q3 24 | -27.4% | -4.1% | ||
| Q2 24 | 18.9% | 2.9% | ||
| Q1 24 | -21.5% | -22.6% |
| Q4 25 | 0.6% | 3.4% | ||
| Q3 25 | 7.8% | 14.7% | ||
| Q2 25 | 10.7% | 0.8% | ||
| Q1 25 | 0.9% | 2.9% | ||
| Q4 24 | 4.7% | 5.3% | ||
| Q3 24 | 1.7% | 0.7% | ||
| Q2 24 | 0.9% | 4.1% | ||
| Q1 24 | 0.7% | 10.7% |
| Q4 25 | — | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -2.28× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BEEM
| Products | $7.0M | 77% |
| Other | $2.0M | 23% |
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
